MapLight Therapeutics, Inc.
MPLTNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MPLT. That does not mean none is planned.
Get an email about MPLT's next catalysts
Track MapLight Therapeutics (MPLT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 1 past
MPLT Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-1.22 | FQ end Sep/2026 | Call: tbd
How MPLT's past catalysts played out
Market Overview
Stock performance and key metrics
ML-007C-MA
Psychosis Associated With Alzheimer's Disease
ML-004 (IR)/(ER) tablet
Autism Spectrum Disorder
ML-007C-MA BID
Schizophrenia
ML-007C-MA QD
Schizophrenia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ML-007C-MA | Phase 2 | Psychosis Associated With Alzheimer's Disease | - | - |
ML-004 (IR)/(ER) tablet | Phase 2 | Autism Spectrum Disorder | - | - |
ML-007C-MA BID | Phase 2 | Schizophrenia | - | - |
ML-007C-MA QD | Phase 2 | Schizophrenia | - | - |
Frequently asked questions
What is in MapLight Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in MapLight Therapeutics, Inc.'s (MPLT) pipeline across Phase 2. Its lead program is ML-004 (IR)/(ER) tablet (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MapLight Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for MapLight Therapeutics, Inc. (MPLT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MPLT biotech catalysts?→
Add MPLT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MapLight Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.